Chances and Limits of Cord Blood Transplantation

  • E. Wunder
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 33)

Abstract

Cord blood (CB) as a new source of grafting material has evoked great expectations. Because it is derived from the fetus, it contains immature cells with unusual properties: they possess higher proliferation capacity for regenerating the hematopoietic system after ablative treatment than does grafting material gained from adults, and they retain differentiation capacities for some non-hematopoietic tissues as well. The main application today is straightforward use as sibling or unrelated allograft during myoablative treatment of malignant disease. Important indications are also given in children with inherited blood cell diseases, hemoglobinopathies, immune deficiencies and other genetic diseases such as osteopetrosis and storage diseases; beside this, new perspectives for tissue replacement in the case of organ damage in adults open up, and both applications foster a family-centered strategy for CB storage.

Keywords

Toxicity Europe DMSO Leukemia Transportation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Douay, McNiece (2000) Contributions at the international conference on haematopoietic stem cell biology and transplantation, Paris, 25–29 March 2000Google Scholar
  2. Gluckman E, Broxmeyer HE, Auerbach AD et al (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321: 1174–1178PubMedCrossRefGoogle Scholar
  3. Gluckman E, Rocha V, Boyer-Chammard A et al (1997) Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 337(6): 373–381PubMedCrossRefGoogle Scholar
  4. Gluckman E, Rocha V, Chastang CL (1999) Umbilical cord blood hematopoietic stem cell transplantation. Eurocord-Cord Blood Transplant Group. Cancer Treat Res 101: 79–96PubMedCrossRefGoogle Scholar
  5. Hénon Ph, Sovalat H, Becker M, Arkam Y, Ojeda-Oribe M, Raidot JP, Husseini F, Wunder E, Bouderont D, Audhuy B (1998) Primordial role of CD34+38-cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol 103: 568–581PubMedCrossRefGoogle Scholar
  6. Kögler G, Somville T, Gobel U, Hackenberg P, Knipper A, Fischer J, Adams O, Krempe C, McKenzi C, Ruttgers H, Meier W, Bellmann O, Streng H, Ring A, Rosseck U, Rocha V, Wernet P (1999) Haematopoietic transplant potential of unrelated and related cord blood: the first six years of the Eurocord/Netcord Bank Germany. Klin Padiatr 211(4): 224–232PubMedCrossRefGoogle Scholar
  7. Kurtzberg J, Laughlin M, Graham ML et al (1996) Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335: 157–166PubMedCrossRefGoogle Scholar
  8. Lampeter EF, Egger D (2000) Storage of cord blood for related or unrelated use. In: Schultze W (ed) High-dose therapy and transplantation of hematopoietic cells. Blackwell Wissenschafts-Verlag, BerlinGoogle Scholar
  9. Leung W, Ramirez M, Civin CI (1999) Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Biol Blood Marrow Transplant 5(2): 69–76PubMedCrossRefGoogle Scholar
  10. Mayani H, Landsdorp PM (1998) Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16: 153–165PubMedCrossRefGoogle Scholar
  11. Nieda M, Nicol A, Denning-Kendall P et al (1997) Endothelial cell precursors are normal components of human umbilical cord blood. Br J Haematol 98: 775–777PubMedCrossRefGoogle Scholar
  12. Piacibello W, Sanavio F, Garetto L et al (1997) Extensive amplification and self renewal of human primitive hematopoietic stem cells from cord blood. Blood 89(8): 2644–2653PubMedGoogle Scholar
  13. Rawlings DJ, Quan SG, Kato RM et al (1995) Long-term culture system for selective growth of human B-cell progenitors. Proc Natl Acad Sci USA 92: 1570–1574PubMedCrossRefGoogle Scholar
  14. Rubinstein P, Carrier C, Scaradavou A et al (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339(22): 1565–1567PubMedCrossRefGoogle Scholar
  15. To LB (1994) Establishment of a clinical threshold cell dose: correlation between CFU-GM and duration of aplasia. In: Wunder E, Sovalat H, Henon PR, Serke S (eds) Hematopoietic stem cells. Mulhouse Manual Alpha Med Press, Dayton OHGoogle Scholar
  16. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM (1994) Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 91: 9857–9860PubMedCrossRefGoogle Scholar
  17. Wagner JE, Rosenthal J, Sweetman R et al (1996) Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 795-802Google Scholar
  18. Wang JCY, Doedens M, Dick JE (1997) Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89: 3919–3924PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • E. Wunder

There are no affiliations available

Personalised recommendations